title: Co-induction of the heat shock response ameliorates disease progression in a mouse model of human spinal and bulbar muscular atrophy: implications for therapy.
abstract: Spinal and bulbar muscular atrophy, also known as Kennedy's disease, is an adult-onset hereditary neurodegenerative disorder caused by an expansion of the polyglutamine repeat in the first exon in the androgen receptor gene. Pathologically, the disease is defined by selective loss of spinal and bulbar motor neurons causing bulbar, facial and limb weakness. Although the precise disease pathophysiology is largely unknown, it appears to be related to abnormal accumulation of the pathogenic androgen receptor protein within the nucleus, leading to disruption of cellular processes. Using a mouse model of spinal and bulbar muscular atrophy that exhibits many of the characteristic features of the human disease, in vivo physiological assessment of muscle function revealed that mice with the pathogenic expansion of the androgen receptor develop a motor deficit characterized by a reduction in muscle force, abnormal muscle contractile characteristics, loss of functional motor units and motor neuron degeneration. We have previously shown that treatment with arimoclomol, a co-inducer of the heat shock stress response, delays disease progression in the mutant superoxide dismutase 1 mouse model of amyotrophic lateral sclerosis, a fatal motor neuron disease. We therefore evaluated the therapeutic potential of arimoclomol in mice with spinal and bulbar muscular atrophy. Arimoclomol was administered orally, in drinking water, from symptom onset and the effects established at 18 months of age, a late stage of disease. Arimoclomol significantly improved hindlimb muscle force and contractile characteristics, rescued motor units and, importantly, improved motor neuron survival and upregulated the expression of the vascular endothelial growth factor which possess neurotrophic activity. These results provide evidence that upregulation of the heat shock response by treatment with arimoclomol may have therapeutic potential in the treatment of spinal and bulbar muscular atrophy and may also be a possible approach for the treatment of other neurodegenerative diseases.
authors: Sobell Department of Motor Neuroscience, MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK. l.greensmith@ucl.ac.uk
authors: Bilal
authors: B
authors: Malik
authors: Niranjanan
authors: N
authors: Nirmalananthan
authors: Anna L
authors: AL
authors: Gray
authors: Albert R
authors: AR
authors: La Spada
authors: Michael G
authors: MG
authors: Hanna
authors: Linda
authors: L
authors: Greensmith
mesh_terms: D000818:Animals; D015153:Blotting, Western; D004195:Disease Models, Animal; D018450:Disease Progression; D006360:Heat-Shock Proteins / Q000378:metabolism*; D018869:Heat-Shock Response / Q000187:drug effects* / Q000502:physiology; D006898:Hydroxylamines / Q000494:pharmacology*; D008297:Male; D051379:Mice; D020966:Muscular Disorders, Atrophic / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D060888:Real-Time Polymerase Chain Reaction
chemical_list: D006360:Heat-Shock Proteins; D006898:Hydroxylamines; D018696:Neuroprotective Agents; C486387:arimoclomol
references: Int J Mol Sci. 2009 Mar;10(3):1000-12
references: 19399234
references: Nat Rev Mol Cell Biol. 2005 Nov;6(11):891-8
references: 16167052
references: Exp Cell Res. 2010 Sep 10;316(15):2424-33
references: 20542028
references: Proc Soc Exp Biol Med. 1998 Apr;217(4):420-34
references: 9521088
references: J Mol Med (Berl). 2004 May;82(5):298-307
references: 15133611
references: J Neurochem. 2008 Jul;106(2):912-6
references: 18466334
references: Brain. 2005 Mar;128(Pt 3):659-70
references: 15659427
references: Nat Med. 2005 Oct;11(10):1088-95
references: 16155577
references: Hum Mol Genet. 2009 Mar 1;18(5):898-910
references: 19066230
references: Hum Mol Genet. 2009 Jun 1;18(11):1937-50
references: 19279159
references: Mol Pharmacol. 2009 May;75(5):1180-8
references: 19188336
references: Nature. 1991 Jul 4;352(6330):77-9
references: 2062380
references: Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
references: 12184808
references: Nat Genet. 2003 Aug;34(4):383-94
references: 12847526
references: Biochem Biophys Res Commun. 2003 Aug 1;307(3):689-95
references: 12893279
references: J Biol Chem. 1997 Jul 18;272(29):18033-7
references: 9218432
references: Int J Cancer. 2009 Nov 1;125(9):2077-85
references: 19598258
references: Nat Neurosci. 2005 Jan;8(1):85-92
references: 15568021
references: FASEB J. 2006 May;20(7):1003-5
references: 16571781
references: Hum Mol Genet. 2008 Feb 1;17(3):345-56
references: 17947294
references: Nat Med. 2004 Apr;10(4):402-5
references: 15034571
references: J Clin Invest. 2011 Aug;121(8):3306-19
references: 21785217
references: Brain. 2008 Jan;131(Pt 1):229-39
references: 18056738
references: Mol Biosyst. 2006 Dec;2(12):627-39
references: 17216044
references: Endocrine. 2001 Mar;14(2):143-9
references: 11394630
references: J Neurosci. 2004 May 19;24(20):4778-86
references: 15152038
references: Lancet Neurol. 2010 Sep;9(9):875-84
references: 20691641
references: Hum Mol Genet. 1999 May;8(5):731-41
references: 10196362
references: Nat Rev Genet. 2005 Oct;6(10):743-55
references: 16205714
references: Hum Mol Genet. 2002 Mar 1;11(5):515-23
references: 11875046
references: Cell Cycle. 2008 Mar 1;7(5):637-46
references: 18239458
references: Hum Mol Genet. 2011 May 1;20(9):1776-86
references: 21317158
references: Neuron. 2002 Aug 29;35(5):843-54
references: 12372280
references: J Neurosci. 2003 Mar 15;23(6):2203-11
references: 12657679
references: Int J Cancer. 2009 Jan 15;124(2):298-305
references: 18844219
references: Hum Mol Genet. 2001 May 1;10(10):1039-48
references: 11331614
references: J Neurochem. 2008 Oct;107(2):339-50
references: 18673445
references: Nature. 2004 Oct 14;431(7010):805-10
references: 15483602
references: Neuron. 2002 Aug 29;35(5):855-64
references: 12372281
references: Brain Res Bull. 2001 Oct-Nov 1;56(3-4):161-3
references: 11719245
references: Hum Mol Genet. 2003 Apr 1;12(7):749-57
references: 12651870
references: Expert Opin Investig Drugs. 2009 Dec;18(12):1907-18
references: 19938902
references: Hum Mol Genet. 2010 Dec 15;19(24):4774-89
references: 20871097
references: Hum Mol Genet. 2006 Jul 15;15(14):2225-38
references: 16772330
references: J Neurosci. 2010 Apr 21;30(16):5702-12
references: 20410122
references: J Clin Invest. 2006 Oct;116(10):2663-72
references: 16981011
references: Neurology. 2008 May 20;70(21):1967-71
references: 18490617
references: J Biol Chem. 2007 Feb 2;282(5):3157-64
references: 17121819
references: Hum Mol Genet. 2010 Sep 1;19(17):3440-56
references: 20570967
references: Nat Med. 2011 Oct 16;17(11):1445-7
references: 22001907
references: J Biol Chem. 2006 Mar 24;281(12):7873-80
references: 16407317
references: Hum Mol Genet. 2001 Jan 15;10(2):107-16
references: 11152658
references: J Biol Chem. 2008 Sep 19;283(38):26188-97
references: 18632670
references: J Biol Chem. 2000 Mar 24;275(12):8772-8
references: 10722721
references: Neurochem Int. 2012 Aug;61(3):321-33
references: 22579571
references: Neuron. 2004 Mar 4;41(5):687-99
references: 15003169
references: J Biol Chem. 2002 Dec 27;277(52):50855-9
references: 12388541
references: Nature. 2004 May 27;429(6990):413-7
references: 15164063
references: Acta Neuropathol. 2010 Oct;120(4):419-37
references: 20514488
references: Neuron. 2003 Feb 6;37(3):383-401
references: 12575948
references: Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16801-6
references: 16260738
references: Muscle Nerve. 2008 Jul;38(1):837-44
references: 18551622
references: J Biol Chem. 2002 Aug 16;277(33):29936-44
references: 12052835
references: Hum Mol Genet. 2003 Jun 15;12(12):1377-91
references: 12783846
references: Neurobiol Dis. 2011 Jan;41(1):83-95
references: 20816782
references: Brain Res. 2011 Jan 12;1368:336-45
references: 20974113
references: Hum Mol Genet. 2000 Jan 1;9(1):133-44
references: 10587588
references: Methods. 2001 Dec;25(4):402-8
references: 11846609
references: J Neurosci. 2006 Nov 22;26(47):12106-17
references: 17122035
references: Neuron. 2002 Aug 29;35(5):819-22
references: 12372277
references: J Neurosci. 2007 May 9;27(19):5115-26
references: 17494697
references: Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5355-8
references: 8202492
references: J Mol Neurosci. 2004;23(1-2):69-96
references: 15126694
references: Hum Mol Genet. 2005 Mar 1;14(5):679-91
references: 15661755
references: Cancer Res. 2005 Jun 1;65(11):4929-38
references: 15930315
references: Neuropathol Appl Neurobiol. 2003 Dec;29(6):529-45
references: 14636160
references: Trends Neurosci. 2008 Oct;31(10):521-8
references: 18778858
references: Brain. 2009 Dec;132(Pt 12):3242-51
references: 19846582
references: Nat Med. 2004 Jul;10 Suppl:S10-7
references: 15272267
references: J Inherit Metab Dis. 1997 Jun;20(2):152-8
references: 9211187
references: Trends Pharmacol Sci. 2010 Nov;31(11):523-7
references: 20863580
references: Neurobiol Dis. 2001 Dec;8(6):933-41
references: 11741389
references: J Clin Oncol. 2005 Jun 20;23(18):4152-61
references: 15961763
references: Nat Rev Neurosci. 2005 Jan;6(1):11-22
references: 15611723
references: Neuroscience. 2005;130(4):897-910
references: 15652988
references: Nat Med. 1997 Oct;3(10):1150-4
references: 9334730
references: Anal Biochem. 1987 Apr;162(1):156-9
references: 2440339